Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Spark Plus Healthcare Day 2025
19 slides from Island Pharmaceuticals's conference presentation, Mar 24, 2025
Slide 1: ASX Announcement: Island Pharmaceuticals conference presentation
24 March 2025 ASX Announcement Island Pharmaceuticals conference presentation MELBOURNE Australia, 24 March 2025: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to provide the attached copy of the Company’s investor presentation
Slide 2: About Island Pharmaceuticals
About Island Pharmaceuticals Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well- established safety profile, being repurposed for the prevention and treatment of den
Slide 3: Combatting Urgent Viral Disease Threats
For personal use only COMBATTING URGENT VIRAL DISEASE THREATS DR DAVID FOSTER, MANAGING DIRECTOR March 2025 (ASX: ILA) ISLAND PHARMACEUTICALS 1 February 2025
Slide 4: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or Future performance Island Pharmaceuticals). This presentation contains certain "forward-looking statements". The words "expect", "anticipate", Not an offer or financia
Slide 5: For personal use only
For personal use only Dengue infects up Major market to 400m per year* potential Island Pharmaceuticals (ASX: ILA) is an antiviral therapeutics company Positive results in Phase 2a/b PROTECT clinical targeting infectious diseases aggressive models trial in dengue underway Priority Review Pipeline ex
Slide 6: Corporate Overview
CORPORATE OVERVIEW Snapshot Price & volume (12 month) For personal use only Share on issue1: 210,259,700 8 0.22 0.20 Price per share1: $0.19 0.18 6 0.16 Market capitalisation1: $39.9m 0.14 Daily Volume (Millions) Cash at bank (31 December 2024)2: $3.99m 0.12 Price ($) 4 0.10 Cash received from 2025
Slide 7: Company Overview
COMPANY OVERVIEW For personal use only - Focused on antiviral therapeutics and infectious disease prevention and treatment - Lead asset, ISLA-101 being repurposed for dengue fever and other mosquito (or vector) borne diseases – opportunities to expand molecule portfolio well advanced - ISLA-101 was
Slide 8: Benefits of Drug Repurposing
BENEFITS OF DRUG REPURPOSING For personal use only ISLAND PHARMACEUTICALS 6 March 2025
Slide 9: Dengue Overview - Infection and Spread Leads to Lethal Outcomes
DENGUE OVERVIEW - INFECTION AND SPREAD LEADS TO LETHAL OUTCOMES For personal use only Uninfected Virus and treatment overview: mosquito • Dengue is a viral infection transmitted to humans through the bite of infected mosquitoes • It directly impacts white blood cell count and platelets - vital for b
Slide 10: Dengue - Common and Spreading
DENGUE - COMMON AND SPREADING For personal use only US$8.9B Estimated impact to the economy from HealthMap: recent reports of local or imported dengue cases (March 2025) dengue fever “About half of the world's population is now at risk of dengue with an estimated 100 – 400 million infections occurri
Slide 11: Dengue by 2050 Is More Prevalent
DENGUE BY 2050 IS MORE PREVALENT For personal use only Driven by: Warmer temperatures • Accelerating development • Increases activity of female mosquitoes • Reduces incubation time for mosquito to become infectious • Allow mosquitoes to survive longer through winter High humidity • Improves mosquito
Slide 12: ISLA-101 - Broad Activity Evident
ISLA-101 – BROAD ACTIVITY EVIDENT For personal use only Demonstrated activity against flaviviruses (subgroup of arboviruses) in models of infection • ISLA-101 has demonstrated broad anti-viral activity in in-vitro models • Demonstrated potent anti dengue-1 activity in in-vitro models using fresh Den
Slide 13: Preventing Animal Deaths from Lethal Dengue and Protective Against Zika
PREVENTING ANIMAL DEATHS FROM LETHAL DENGUE AND PROTECTIVE AGAINST ZIKA For personal use only Survival curve showing protection from lethal dengue change by Increasing dose of ISLA101 (mouse model). Fraser et al. J. Infect. Dis 2014 ISLAND PHARMACEUTICALS 11 March 2025
Slide 14: Phase 2a/b (PROTECT) Study Overview
PHASE 2A/B (PROTECT) STUDY OVERVIEW For personal use only Randomised, double blind, placebo-controlled dengue challenge study – prophylactic and treatment challenge: • Study structured to include both a prophylactic (Phase 2a) and therapeutic (Phase 2b) arm • Prophylactic Cohort- 2a: 4 subjects rand
Slide 15: Phase 2a/b (PROTECT) Design
PHASE 2A/B (PROTECT) DESIGN Phase 2A: Prophylactic (preventative) cohort Administer ISLA-101 daily For personal use only Strong progress to date with results pending: • Phase 1 (completed April 2024) achieved all study outcomes relating to safety and dosing, demonstrating benefit of Challenge study
Slide 16: Clinical Trial and Regulatory Pathway
CLINICAL TRIAL AND REGULATORY PATHWAY For personal use only A defined clinical and regulatory route based on Phase 2a/b study results • Two likely pathways depending on Phase 2a/b results • Discussions advancing with multiple potential strategic partners for additional phase 2 and 3 clinical trials
Slide 17: Galidesivir - Significant Pipeline Opportunity
GALIDESIVIR - SIGNIFICANT PIPELINE OPPORTUNITY For personal use only Galidesivir – potential to tackle Ebola, Marburg, Zika & other RNA viruses - 12-month binding LOI signed in Sept 2024 - Small molecule, re-purposable with reduced timeframe to market - Substantial Phase 1 human safety data - Proven
Slide 18: Near Term Milestones
NEAR TERM MILESTONES For personal use only A number of value catalysts pending in the coming months Milestone Timeframe Clinical update on Phase 2a/b study April 2025 Advancement of Galidesivir opportunity May 2025 Full, unblinded results from Phase 2a/b PROTECT study Q2 CY2025 Meeting with US FDA t
Slide 19: Island Pharmaceuticals
For personal use only Island Pharmaceuticals (ASX: ILA) islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals ISLAND PHARMACEUTICALS 17 March 2025
Island Pharmaceuticals — Spark Plus Healthcare Day 2025 on 6ix